Translate

Colorectal Cancer Market and Industry Analysis with Global Outlook (2021-2025)

"Global Colorectal Cancer Market: Industry Analysis & Outlook (2021-2025)" The Report covers current Industries Trends, Worldwide Analysis, Global Forecast, Review, Share, Size, Growth, Effect.

Description-

Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). A cancer is the abnormal growth of cells that has the ability to invade or spread to other parts of the body. Signs and symptoms for this cancer may include blood in the stool, a change in bowel movements, weight loss, and feeling tired all the time. The current screening regime for this disease comprises of gFOBT, FIT, flexible Sigmoidoscopy, Colonoscopy and others. Further, the treatment for CRC is limited to surgery, chemotherapy and radiotherapy or adjuvant therapies.


The global CRC market would be driven by factors such as rising geriatric population, better reimbursement policies, growing number of obese people and others. However, the dynamics such as stringent regulatory norms, side effects of therapies and high cost of screening tests or drugs are expected to act as a threat for market’s growth. Rising awareness regarding the incidence of CRC and importance of diagnosis has propelled higher compliance with regular tests.

Further, in order to harness the market potential, various companies are involved in developing lesser invasive and easy to use screening methods.
The report “Global Colorectal Cancer Market: Industry Analysis & Outlook (2021-2025)” provides a comprehensive study of global market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in-depth. The global market is highly competitive consisting of several large enterprises including Bayer AG, Roche Holding AG, Merck & Co., Inc. and Eli Lilly and Company. The competitive landscape of the respective market, along with the company profiles of leading players are discussed in detail.

- Table of Content
1. Overview
1.1 Colorectal Cancer
1.2 Signs, Symptoms and Stages
1.3 Diagnosis
1.4 Treatment
 
2. Global Colorectal Cancer Market
2.1 Global Cancer Diagnostics Market Forecast by Value
2.2 Global CRC Screening Patient Volume Forecast
2.3 Global CRC Screening Patient Volume by Region
2.4 Global CRC Screening Product Market
2.4.1 Global C-Scan Cap Revenue Forecast
2.5 Global CRC Patients on Drugs by Volume
2.6 Global CRC Patients on Drugs by Region
2.7 Global CRC Patients on Drugs by Segments
2.8 Global CRC Drug Market
2.8.1 Global Modufolin Revenue Forecast
2.8.2 Global Modufolin Revenue Forecast by Segments
2.8.3 Global Modufolin Revenue as First Line Drug
2.8.4 Global Modufolin Revenue as Second Line Drug
2.8.5 Global Modufolin Revenue as Third Line Drug

3. Regional Market
3.1 The US
3.1.1 The US CRC Screening Patient Volume Forecast
3.1.2 The US CRC Screening Volume by Test Mix
3.1.3 The US C-Scan Cap Revenue Forecast
3.1.4 The US Patients on First Line CRC Drug by Volume
3.1.5 The US Patients on Second Line CRC Drug by Volume
3.1.6 The US Patients on Third Line CRC Drug by Volume
3.2 Europe
3.2.1 Europe CRC Screening Patient Volume Forecast
3.2.2 Europe C-Scan Cap Revenue Forecast
3.2.3 Europe Patients on First Line CRC Drug by Volume
3.2.4 Europe Patients on Second Line CRC Drug by Volume
3.2.5 Europe Patients on Third Line CRC Drug by Volume

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Growing Geriatric Population
4.1.2 Rising Healthcare Expenditure
4.1.3 Growing Global GDP per Capita
4.1.4 Surging Obese Population
4.1.5 Rising Awareness Regarding CRC
4.2 Key Trends & Development
4.2.1 Rising Compliance to CRC Screening
4.2.2 Development of New CRC Drugs
4.3 Challenges
4.3.1 High Cost of Screening and Drugs
4.3.2 Side Effects of Drugs
4.3.3 Stringent Drug Approval Process

5. Competitive Landscape
5.1 Global CRC Market
5.1.1 Revenue and Market Cap. Comparison
5.2 Global CRC Drugs Market
5.1.2 Global CRC Drugs Market by Company Share
5.3 Global CRC Screening Market
5.3.1 DNA based CRC Screening Tests Comparison

6. Company Profiles
6.1 Bayer AG
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Roche Holding AG
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Merck & Co., Inc.
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Eli Lilly and Company
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies



- List of Table

Revenue and Market Cap. Comparison (2016)
DNA based CRC Screening Tests Comparison (2016)
Allergan Plc. Body Contouring Key Product Comparison (2017)
Number of Products in Pipeline by Segments (2016)


- List of Chart

Stages of Colorectal Cancer
Treatment Option for Colorectal Cancer
Global Cancer Diagnostics Market Forecast by Value (2021-2025)
Global CRC Screening Patient Volume Forecast (2021-2025)
Global CRC Screening Patient Volume by Region (2021)
Global C-Scan Cap Revenue Forecast (2021-2025)
Global CRC Patients on Drugs by Volume (2021-2025)
Global CRC Patients on Drugs by Region (2021)
Global CRC Patients on Drugs by Segments (2021)
Global Modufolin Revenue Forecast by Value (2021-2025)
Global Modufolin Revenue Forecast by Segments (2021/2025)
Global Modufolin Revenue as First Line Drug (2021-2025)
Global Modufolin Revenue as Second Line Drug (2021-2025)
Global Modufolin Revenue as Third Line Drug (2023-2025)
The US CRC Screening Patient Volume Forecast (2021-2025)
The US CRC Screening Volume by Test Mix (2016)
The US C-Scan Cap Revenue Forecast (2021-2025)
The US Patients on First Line CRC Drug by Volume (2021-2025)
The US Patients on Second Line CRC Drug by Volume (2021-2025)
The US Patients on Third Line CRC Drug by Volume (2021-2025)



Comments

Post a Comment